Never Miss a Potential Recovery Again

Sign up for Class
Action Alerts

Each year, class action lawsuits generate billions of dollars in settlement funds, but many shareholders fail to file a claim. Stay in the know regarding class action lawsuits by signing up for alerts.

There is no cost or obligation for you to submit. No spam will be sent to your email.

$926,950,000 in Total Settlement Funds Available. See if you qualify!Find Out More

We Give Shareholders A Voice.

The market fluctuates, but we don’t. We give you straight answers from real attorneys who have spent decades helping shareholders protect their investments and recover their losses.

Settlements

$47.5 Million

QuantumScape Corporation

$24.6 Million

Loma Negra Industrial Argentina Sociedad Argentina

$14 Million

Corcept Therapeutics Incorporated

$9.5 Million

Babcock & Wilcox Enterprises, Inc.

$40 Million

U.S. Steel

$7 Million

Aqua Metals, Inc.

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

I think you’ve done a superb job and I really appreciate the way this case was handled.

The Honorable Ronald B. Rubin in Teoh v. Ferrantino, C.A. No. 356627 (Cir. Ct. for Montgomery Cnty., MD 2012)

…a model for how [the] great legal profession should conduct itself.

Justice Timothy S. Driscoll in Grossman v. State Bancorp, Inc., Index No. 600469/2011 (N.Y. Sup. Ct. Nassau Cnty. Nov. 29, 2011)

I find the firm to be well-qualified to serve as Lead Counsel.

The Honorable Andrew L. Carter, Jr. In Snyder v. Baozun Inc., No. 1:19-CV-11290 (S.D.N.Y. Sept. 8, 2020)

In appointing the Firm Lead Counsel, the Honorable Analisa Torres noted our “extensive experience” in securities litigation.

White Pine Invs. v. CVR Ref., LP, No. 20 CIV. 2863 (S.D.N.Y. Jan. 5, 2021)

Class Counsel have demonstrated that they are skilled in this area of the law and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management, kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec. Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

Who We Are

We combine specialized securities expertise with an innovative approach to litigation and an enduring commitment to our clients. We represent individuals, institutions, and asset managers in some of the largest, most complex securities cases in the country and never shy away from an uphill battle.

1
1
1
1
1
1

We're here for you

Find an Attorney

Required Field

Coin Image

Don't hesitate

Find a Case

Upcoming Deadlines

Investors interested in taking an active role in litigation have a limited time to petition the court for appointment as lead plaintiff. If you are interested in acting as a lead plaintiff, submit your transactions before the deadline, and our analysts will calculate your losses. Don't wait till the last minute- discuss your options today.
View All Deadlines

2

Days Left

OST

Ostin Technology Group Co., Ltd.

Deadline

April 17 2026

Class Period

5/11/25 - 6/26/25

Allegations

(a) defendants and other select investors were conspiring on the receipt and subsequent sale of OST shares obtained through the registered direct offering and the warrant exchange agreement during a campaign to artificially inflate OST's stock price; and (b) defendants were conspiring to assist co-conspirators with setting up brokerage accounts to eventually dump OST shares obtained as part of the registered direct offering and warrant exchange agreement.

Class Period

5/11/25 - 6/26/25

Deadline

April 17 2026

Learn More

5

Days Left

SMR

NuScale Power Corporation

Deadline

April 20 2026

Class Period

5/13/25 - 11/6/25

Allegations

(a) ENTRA1 Energy LLC (“ENTRA1”) had never built, financed, or operated any significant projects – let alone projects in the highly technical and complicated field of nuclear power generation – during its entire operating history; (b) NuScale had entrusted its commercialization, distribution, and deployment of its NuScale Power Modules and hundreds of millions of dollars of Company capital to an entity that lacked any significant prior experience owning, financing, or operating nuclear energy generation facilities; (c) the purported experience and qualifications attributed to ENTRA1 by defendants during the Class Period in fact referred to the purported experience and qualifications of the principals of the Habboush Group, a distinct entity without significant experience in the field of nuclear power generation; and (d) as a result of (a)-(c) above, NuScale’s commercialization strategy was exposed to material, undisclosed risks of failure, delays, regulatory challenges, or other negative setbacks.

Class Period

5/13/25 - 11/6/25

Deadline

April 20 2026

Learn More

5

Days Left

ENPH

Enphase Energy, Inc.

Deadline

April 20 2026

Class Period

4/22/25 - 10/28/25

Allegations

(i) Enphase overstated its ability to manage its channel inventory; (ii) Enphase overstated its ability to mitigate effects arising from the termination of the 25D Credit; (iii) accordingly, Enphase overstated its financial and operational prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

4/22/25 - 10/28/25

Deadline

April 20 2026

Learn More

5

Days Left

PYPL

PayPal Holdings, Inc.

Deadline

April 20 2026

Class Period

2/25/25 - 2/2/26

Allegations

According to the complaint, defendants provided investors with material information concerning PayPal’s expected financial targets for 2027 alongside the growth trajectory for its core branded checkout segment (“Branded Checkout”). Defendants’ statements included, among other things, confidence in PayPal’s ability to capitalize on its growth potential through new initiatives to facilitate Branded Checkout growth both in the U.S. and internationally. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of PayPal’s salesforce; notably, that it was not truly equipped to execute on the Company’s perceived growth potential and were “too optimistic” as to how easily and expeditiously its staff could change customer adoption On February 3, 2026, PayPal announced its financial results for the fourth quarter and full fiscal year 2025, unveiling disappointing earnings results with worsening performance in Branded Checkout. The Company also unveiled a sudden and surprising transition of its Chief Executive Officer role alongside the below-expectation results. PayPal further withdrew its 2027 financial targets provided one year before and announced projections that suggested a slowdown against those prior targets. PayPal attributed its results and lowered guidance to a combination of macroeconomic factors competition, and “operational and deployment issues” across all regions. Following this news, the price of PayPal’s common stock declined dramatically. From a closing market price of $52.33 per share on February 2, 2026, PayPal’s stock price fell to $41.70 per share on February 3, 2026, a decline of about 20.31% in the span of just a single day.

Class Period

2/25/25 - 2/2/26

Deadline

April 20 2026

Learn More

6

Days Left

CORT

Corcept Therapeutics Incorporated

Deadline

April 21 2026

Class Period

10/31/24 - 12/30/25

Allegations

According to the filed complaint, defendants made false statements and/or concealed that: In light of the circumstances in which they were made, not false and misleading. In truth, the FDA had told Corcept that it had concerns about the adequacy of the program assessing relacorilant’s effectiveness in treating hypertension in patients with hypercortisolism, including the design of the GRACE study. The FDA had further told Corcept to expect significant issues with the review if Corcept was to submit the NDA. As a result, Defendants’ positive statements concerning their interactions with the FDA and their expectations that the relacorilant NDA would be approved, were materially false or misleading.

Class Period

10/31/24 - 12/30/25

Deadline

April 21 2026

Learn More

6

Days Left

ZYXIQ

Zynex, Inc.

Deadline

April 21 2026

Class Period

2/25/21 - 12/15/25

Allegations

(a) Zynex shipped products, including electrodes, in excess of need; (b) as a result of this practice, the Company inflated its revenue; (c) the Company’s practice of filing false claims drew scrutiny from insurers, including the health insurance program, Tricare; (d) on August 21, 2023, Travelers commenced an action against Zynex, Sandgaard, Lucsok and Fox in the Superior Court of California alleging that Zynex and the defendants had embarked on a fraudulent overbilling scheme and seeking more than $23 million in damages and civil penalties relating to hundreds of fraudulent claims between 2018 and 2023; (e) management had prioritized aggressive sales strategies to drive orders over compliance with industry laws, rules and regulations; (f) the Company was not committed to maintaining a strong internal control environment; (g) the Company’s order growth was a result of illegal overbilling; (h) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (i) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. The audit committee defendants, acting knowingly or with reckless disregard of the underlying fraud, helped the insiders bolster the Company’s stock price through stock repurchase plans, and even by buying back millions of dollars worth of stock directly from Sandgaard, indicating their supposed belief that the stock was undervalued.

Class Period

2/25/21 - 12/15/25

Deadline

April 21 2026

Learn More

9

Days Left

LAKE

Lakeland Industries, Inc.

Deadline

April 24 2026

Class Period

12/1/23 - 12/9/25

Allegations

(i) Lakeland was experiencing significant, sustained issues with its Pacific Helmets and Jolly businesses, including, inter alia, shipping-related delays, production issues, and slower than expected rollout of new products; (ii) accordingly, defendants overstated the anticipated and actual positive impact of these businesses on Lakeland’s financial results, as well as the overall strength and quality of Pacific Helmets’ and Jolly’s respective operations; (iii) Lakeland’s business and financial results were significantly deteriorating because of, inter alia, tariff-related headwinds and timing, certification delays, and material flow issues in its acquired businesses; (iv) accordingly, defendants overstated the strength of their tariff mitigation measures and SSQ M&A strategy; (v) as a result of all the foregoing issues, defendants’ financial guidance was unreliable; and (vi) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

12/1/23 - 12/9/25

Deadline

April 24 2026

Learn More

9

Days Left

NAVN

Navan, Inc.

Deadline

April 24 2026

Class Period

This lawsuit is on behalf of all persons of the class who purchased or acquired Navan’s shares pursuant and traceable to the offering on October 30, 2025.

Allegations

According to the filed complaint, at the time of the offering, the Company had increased its sales and marketing expenses. As the truth about the Companys business reached the market, the value of its shares declined dramatically, causing Navan investors to suffer significant damages. Indeed, by the commencement of the action, Navans shares traded as low as $9.01 per share, representing a decline of over 60% from the Offering Price.

Class Period

This lawsuit is on behalf of all persons of the class who purchased or acquired Navan’s shares pursuant and traceable to the offering on October 30, 2025.

Deadline

April 24 2026

Learn More

12

Days Left

SNOW

Snowflake Inc.

Deadline

April 27 2026

Class Period

6/27/23 - 2/28/24

Allegations

(1) product efficiency gains, Iceberg Tables, an open-source table format for large datasets that allow customers to store data in their own cloud, and tiered storage pricing were expected to have a material negative impact on consumption and revenues, and (2) as a result, defendants’ positive statements about consumption patterns, revenues, and demand for Snowflake products lacked a reasonable basis.

Class Period

6/27/23 - 2/28/24

Deadline

April 27 2026

Learn More

12

Days Left

FBRT

Franklin BSP Realty Trust, Inc.

Deadline

April 27 2026

Class Period

11/5/24 - 2/11/26

Allegations

(1) defendants recklessly overstated Franklin BSP Realty Trust’s prospects; (2) defendants recklessly overstated Franklin BSP Realty Trust’s ability to maintain the $0.355 dividend; and (3) as a result, defendants’ statements about Franklin BSP Realty Trust’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

11/5/24 - 2/11/26

Deadline

April 27 2026

Learn More

16

Days Left

APO

Apollo Global management, Inc.

Deadline

May 1 2026

Class Period

5/10/21 - 2/21/26

Allegations

(1) defendants, among other leadership figures at Apollo Global, frequently communicated with Jeffrey Epstein in the 2010s regarding Apollo Global’s business; (2) as a result, Apollo Global’s assertion that the Company had never done business with Jeffrey Epstein was untrue; (3) because of the entanglement between Apollo Global’s leaders and Jeffrey Epstein, the harm to Apollo Global’s reputation was more than a mere possibility; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

5/10/21 - 2/21/26

Deadline

May 1 2026

Learn More

19

Days Left

AQST

Aquestive Therapeutics, Inc.

Deadline

May 4 2026

Class Period

6/16/25 - 1/8/26

Allegations

According to the complaint, defendants provided investors with positive statements while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Aquestive’s New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film; pertinently, Aquestive concealed or otherwise minimized the significance of the human factors involved in the use and deployment of its sublingual film, such as packaging, use, administration, and labeling. On January 9, 2026, Aquestive announced that the Company was in receipt of a letter from the FDA identifying deficiencies that precluded labeling discussions for Anaphylm. Moreover, Aquestive revealed that the letter from the FDA confirmed that the Agency’s review of Anaphylm NDA was ongoing and no final decision had been made, which effectively delayed the approval of Anaphylm well beyond the January 31, 2026 Prescription Drug User Fee Act date. Following this news, the price of Aquestive’s common stock declined dramatically. From a closing market price of $6.21 per share on January 8, 2026, Aquestive’s stock price fell to $3.91 per share on January 9, 2026, a decline of over 37% in a single day.

Class Period

6/16/25 - 1/8/26

Deadline

May 4 2026

Learn More

19

Days Left

BSX

Boston Scientific Corporation

Deadline

May 4 2026

Class Period

7/23/25 - 2/3/26

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Boston Scientific’s U.S. EP segment; notably, that management was aware that the segment’s growth rate was unsustainable and that it was approaching an earlier tipping point than the market was anticipating. Due to defendants’ statements of confidence and lofty expectations, investors and analysts were left surprised by Boston Scientific’s net income miss and underwhelming guidance for the first half of fiscal 2026. On February 4, 2026, Boston Scientific published a press release announcing fourth quarter and full year 2025 results, including a pertinent disappointment in U.S. EP sales, and issued guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and dismal guidance on a combination of slower than expected market growth alongside increased competition, despite management’s previous claims of a “growing” EP business and assertions they “have a very good understanding of what competition we will face and in what time frame.” Following this news, the price of Boston Scientific’s common stock declined dramatically. From a closing market price of $91.62 per share on February 3, 2026, Boston Scientific’s stock price fell to $75.50 per share on February 4, 2026, a decline of about 17.6% in the span of just a single day.

Class Period

7/23/25 - 2/3/26

Deadline

May 4 2026

Learn More

20

Days Left

SLNO

Soleno Therapeutics, Inc.

Deadline

May 5 2026

Class Period

3/26/25 - 11/4/25

Allegations

(a) the Soleno Phase 3 clinical trial program for product diazoxide choline extended-release tablets, DCCR, had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (b) as a result of (a) above, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by the Company or its executives; and (c) as a result of (a)-(b) above, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.

Class Period

3/26/25 - 11/4/25

Deadline

May 5 2026

Learn More

20

Days Left

NKTR

Nektar Therapeutics

Deadline

May 5 2026

Class Period

2/26/25 - 12/15/25

Allegations

(i) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (ii) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial’s results; (iii) accordingly, the REZOLVE-AA trial’s overall integrity and prospects were overstated; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

2/26/25 - 12/15/25

Deadline

May 5 2026

Learn More

20

Days Left

EOSE

Eos Energy Enterprises, Inc.

Deadline

May 5 2026

Class Period

11/5/25 - 2/26/26

Allegations

(1) the Company was unable to achieve the ramp in production and capacity utilization required to achieve its previously set guidance; (2) the Company’s battery line downtime was running well above industry norms, the design intent of the line, and internal forecasts; (3) the Company was experiencing delays in the ability for its automated bipolar production to hit quality targets; (4) the Company’s inadequate systems and processes prevented it from ensuring reasonably accurate guidance and that its public disclosures were timely, accurate, and complete; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/5/25 - 2/26/26

Deadline

May 5 2026

Learn More

23

Days Left

DRVN

Driven Brands Holdings Inc.

Deadline

May 8 2026

Class Period

5/9/23 - 2/24/26

Allegations

According to the filed complaint, defendants misled investors as to the Company’s financial condition and the effectiveness of its internal controls over financial reporting through a series of inaccurate financial reports filed with the Securities and Exchange Commission from May 9, 2023, to November 5, 2025. Among many other errors, the Company’s balance sheets contained an unreconciled cash balance originating in 2023 which resulted in revenue and cash being overstated in 2023 and 2024, and operating expenses being understated over the same period.

Class Period

5/9/23 - 2/24/26

Deadline

May 8 2026

Learn More

26

Days Left

CWH

Camping World Holdings, Inc.

Deadline

May 11 2026

Class Period

4/29/25 - 2/24/26

Allegations

(i) the Company overstated its ability to “surgically manage [its] inventory” to optimize profit using “data analytics;” (ii) the Company overstated the retail demand of consumers it was experiencing and/or reasonably expected; (iii) as a result, the Company would require “strict, corrective inventory management objectives,” negatively impacting gross profit and margins; (iv) the Company’s inadequate systems and processes prevented it from ensuring reasonably accurate disclosures and/or guidance, including about the health of its balance sheet and/or the ability to manage selling, general & administrative expenses; and (v)as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

4/29/25 - 2/24/26

Deadline

May 11 2026

Learn More

26

Days Left

MNDY

monday.com Ltd.

Deadline

May 11 2026

Class Period

9/17/25 - 2/6/26

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of monday’s revenue expansion outlook; notably decelerating growth, reduced expansion momentum and extended sales cycles. On November 10, 2025, monday issued a press release announcing positive financial results for the third quarter 2025. In pertinent part, the Company reported revenue of $316.9 million, an increase of 26% year-over-year, and above consensus of 24%. Despite this positive news, the Company issued softer guidance for the fourth quarter 2025 due to a shift in its performance marketing strategy. Following this news, monday’s stock price declined from $189.59 per share to $166.21 per share on November 10, 2025. On February 9, 2026, defendants issued a press release reporting positive results for the fourth quarter and fiscal year 2025. Notably in the same release, defendants announced a weaker outlook for the Company’s 2026 guidance and a strategic shift away from its long term 2027 revenue target of $1.8 billion. Following this news, the price of monday’s common stock declined dramatically from a closing market price of $98.00 per share on February 6, 2026, monday’s stock price fell to $77.63 per share on February 9, 2026, a decline of about 21%.

Class Period

9/17/25 - 2/6/26

Deadline

May 11 2026

Learn More

26

Days Left

TCOM

Trip.com Group Limited

Deadline

May 11 2026

Class Period

4/30/24 - 1/13/26

Allegations

(1) defendants recklessly understated the regulatory risk facing Trip.com as a result of its monopolistic business activities; and (2) as a result, defendants’ statements about Trip.com’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

4/30/24 - 1/13/26

Deadline

May 11 2026

Learn More

26

Days Left

ODD

ODDITY Tech Ltd.

Deadline

May 11 2026

Class Period

2/26/25 - 2/24/26

Allegations

(i) due to an algorithm change by Oddity’s largest advertising partner, Oddity’s advertisements were being diverted to lower quality auctions at abnormally high costs; (ii) the foregoing significantly increased Oddity’s customer acquisition costs, thereby negatively impacting Oddity’s business and financial prospects; (iii) accordingly, defendants overstated the overall strength, stability, and sustainability of Oddity’s digital operating model and/or market position; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

2/26/25 - 2/24/26

Deadline

May 11 2026

Learn More

27

Days Left

CHOW

ChowChow Cloud International Holdings Limited

Deadline

May 12 2026

Class Period

9/16/25 - 12/10/25

Allegations

(1) CHOW was the subject of a market manipulation and fraudulent promotion scheme involving social-media based misinformation and impersonators posing as financial professionals; (2) CHOW’s public statements and risk disclosures omitted any mention of the realized risk of fraudulent trading or market manipulation used to drive the Company’s stock price; (3) as a result, CHOW securities were at unique risk of a sustained suspension in trading by NYSE American and severe volatility-induced decline; (4) the sole underwriter on the IPO, Tiger Securities, had been fined and censured by the financial industry regulatory authority in April 2025 for failing to have a reasonable system in place to identify potentially suspicious deposits of low-priced securities; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

9/16/25 - 12/10/25

Deadline

May 12 2026

Learn More

30

Days Left

GO

Grocery Outlet Holding Corp.

Deadline

May 15 2026

Class Period

8/5/25 - 3/4/26

Allegations

(1) the Company had “expanded too quickly” into new stores; (2) the Company’s purportedly strong financial and operational growth was being artificially supported by excessive rapid store expansion; (3) as a result, the Company was unable to achieve the sustainable growth required to meet its previously set guidance; (4) the Company’s restructuring plan would require further optimization to achieve its operational goals, including significant store closures and asset write-downs; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

8/5/25 - 3/4/26

Deadline

May 15 2026

Learn More

30

Days Left

ALIT

Alight, Inc.

Deadline

May 15 2026

Class Period

11/12/24 - 2/18/26

Allegations

According to the complaint, throughout the class period, defendants announced disappointing results, reduced projections, and multiple goodwill impairments all while remaining confident in their ability to execute, drive growth, and continue to provide a dividend to their shareholders. On August 5, 2025, during Alight’s second quarter earnings report, defendants announced disappointing results and cut their revenue guidance for the year, resetting investor expectations. Defendants highlighted both a slowdown in annual recurring revenue bookings and a worsening decline of project revenue than previously projected. Pertinently, defendants pointed partially to macroeconomic uncertainty, though they had previously minimized such impact in just the prior quarter, as well as insufficient commercial execution. Following this news, the price of Alight’s common stock declined dramatically. From a closing market price of $5.13 per share on August 4, 2025, Alight’s stock price fell to $4.19 per share on August 5, 2025, a decline of about 18.32% in the span of just a single day. On February 19, 2026, Alight announced a significant earnings shortfall against its prior guidance, alongside further shortfalls for bookings and project revenue growth. Alight’s new management noted the Company failed to “meet our internal financial targets and new bookings and renewals did not meet our expectations, leading us to miss our forecast to the market.” They pointed the blame significantly on the individual defendants’ execution and highlighted the new administration would bring “a change in the execution of the company” in order to “driv[e] operational excellence.” The new management further cancelled the dividend, noting there are “more efficient capital allocation activities,” and triggered an earnings shortfall due to “an increase in compensation expense” in order to “promot[e] service quality,” and overall improve sales execution. Following this news, the price of Alight’s common stock declined dramatically. From a closing market price of $1.31 per share on February 18, 2026, Alight’s stock price fell to $0.81 per share on February 19, 2026, a decline of nearly 38% in the span of one day. Notably, the stock had now fallen approximately $6.85, or nearly 90% over the course of the instant class period.

Class Period

11/12/24 - 2/18/26

Deadline

May 15 2026

Learn More

33

Days Left

IT

Gartner, Inc.

Deadline

May 18 2026

Class Period

2/4/25 - 2/2/26

Allegations

According to the complaint, throughout the class period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Gartner’s growth rates; notably, that it was not truly equipped to handle ongoing challenges in its industry to either meet consulting revenue targets or to increase or even maintain its expected contract value (“CV”) growth rate; Gartner’s repeated claims of being able to achieve 12-16% CV growth rates in a “normal” macroeconomic environment proved to be unrealistic. On August 5, 2025, during Gartner’s earnings call following a same day press release announcing its second quarter fiscal 2025 earnings, defendants announced a surprising decline in their CV growth rate, both when considering contracts with the federal government and when excluding them. Specifically, defendant’s overall CV growth declined from 7% the previous quarter to only 5%; mirroring, the ex-federal CV growth declined from 8% the previous quarter to merely 6%. Following this news, the price of Gartner’s common stock declined dramatically. From a closing market price of $336.71 per share on August 4, 2025, Gartner’s stock price fell to $243.93 per share on August 5, 2025, a decline of about 27.55% in the span of just a single day. On February 3, 2026, Gartner again announced a significant decline in its CV growth rate, which had faltered another 2% both including and excluding federal contracts, and for the first time disclosed a significant shortfall of its Consulting segment’s performance against the Company’s internal projections. Following this news, the price of Gartner’s common stock declined dramatically. From a closing market price of $202.40 per share on February 2, 2026, Gartner’s stock price fell to $160.16 per share on February 3, 2026, a decline of nearly 20.87% in the span of one day.

Class Period

2/4/25 - 2/2/26

Deadline

May 18 2026

Learn More

33

Days Left

CIGL

Concorde International Group, Ltd.

Deadline

May 18 2026

Class Period

4/21/25 - 7/14/25

Allegations

(1) Concorde was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) Concorde’s public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

4/21/25 - 7/14/25

Deadline

May 18 2026

Learn More

33

Days Left

GEMI

Gemini Space Station, Inc.

Deadline

May 18 2026

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Gemini Class A common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about September 12, 2025; and/or Gemini securities between September 12, 2025 and February 17, 2026, both dates inclusive.

Allegations

(i) Gemini had overstated the viability of its core business as a crypto platform; (ii) Gemini had overstated its commitment to and/or the viability of growing its business through expanding its international operations; (iii) accordingly, Gemini’s post-IPO financial and business prospects were overstated; (iv) all of the foregoing raised a non-speculative risk that Gemini was poised for an expensive and disruptive restructuring; and (v) as a result, the offering documents and defendants’ public statements throughout the class period were materially false and misleading at all relevant times.

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Gemini Class A common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about September 12, 2025; and/or Gemini securities between September 12, 2025 and February 17, 2026, both dates inclusive.

Deadline

May 18 2026

Learn More

34

Days Left

HTGC

Hercules Capital, Inc.

Deadline

May 19 2026

Class Period

5/1/25 - 2/27/26

Allegations

(1) the Company overstated the due diligence with which it conducted its deal sourcing and/or loan origination process; (2) the Company overstated the due diligence with which it conducted its portfolio valuation process; (3) the Company reported misclassified portfolio investments; (4) as a result of the foregoing, the Company overstated and/or misrepresented its portfolio valuations; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/1/25 - 2/27/26

Deadline

May 19 2026

Learn More

34

Days Left

PSIX

Power Solutions International, Inc.

Deadline

May 19 2026

Class Period

5/8/25 - 3/2/26

Allegations

(1) the Company overstated its ability to capture sales demand for its power systems solutions, particularly within the data center market; (2) the Company understated the impact of its enhancements to manufacturing capacity to meet demand within the data center market, including the expected costs and the nature of the related “inefficiencies”; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/8/25 - 3/2/26

Deadline

May 19 2026

Learn More

35

Days Left

LU

Lufax Holding Ltd

Deadline

May 20 2026

Class Period

4/7/23 - 1/26/25

Allegations

(1) Lufax lacked adequate internal controls; (2) certain of Lufax’s financial results were materially misstated; and (3) as a result, defendants’ statements about Lufax’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

4/7/23 - 1/26/25

Deadline

May 20 2026

Learn More

37

Days Left

ATRA

Atara Biotherapeutics, Inc.

Deadline

May 22 2026

Class Period

5/20/24 - 1/9/26

Allegations

(i) certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (ii) accordingly, tabelecleucel’s regulatory prospects were overstated; (iii) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical trials; (iv) all the foregoing was likely to have a significant negative impact on Atara’s business and financial condition; and (v) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

5/20/24 - 1/9/26

Deadline

May 22 2026

Learn More

37

Days Left

COTY

Coty Inc.

Deadline

May 22 2026

Class Period

11/5/25 - 2/4/26

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Coty’s slowing growth in the beauty market, notably, the Consumer Beauty market was underperforming, margins were compressed by increased marketing investments and there was slowing growth in its Prestige fragrance segment.

After the market closed on February 4 and 5, 2026, Coty announced its financial results for the second quarter fiscal year 2026, unveiling disappointing earnings results with worsening performance in the Consumer Beauty segment. The Company also noted the recent transition of its Chief Executive Officer in conjunction with the below-expectation results. Coty further withdrew its fiscal year 2026 guidance for EBITDA and revised the Company’s near-term outlook downward. Coty attributed its results and lowered guidance to a combination of macroeconomic factors including rising costs and uncertain consumer demand and lack of “operational discipline” in both Prestige and Consumer Beauty segments.

Following this news, the price of Coty’s common stock declined from a closing market price of $3.43 per share on February 4, 2026, to $2.66 per share on February 6, 2026, a decline of about 22%.

Class Period

11/5/25 - 2/4/26

Deadline

May 22 2026

Learn More

40

Days Left

SMCI

Super Micro Computer, Inc.

Deadline

May 25 2026

Class Period

2/2/24 - 3/19/26

Allegations

(1) a significant portion of the Company’s sales of servers were to companies based in China; (2) these transactions violated U.S. export control laws; (3) there were material weaknesses in the Company’s controls to ensure compliance with applicable export control laws and regulations; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

2/2/24 - 3/19/26

Deadline

May 25 2026

Learn More

41

Days Left

IBRX

ImmunityBio, Inc.

Deadline

May 26 2026

Class Period

1/19/26 - 3/24/26

Allegations

(1) defendant Soon-Shion materially overstated Anktiva’s capabilities; and (2) as a result, defendants’ statements about ImmunityBio’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

1/19/26 - 3/24/26

Deadline

May 26 2026

Learn More

41

Days Left

VITL

Vital Farms, Inc.

Deadline

May 26 2026

Class Period

5/8/25 - 2/26/26

Allegations

(1) defendants emphasized the importance of the enterprise resource planning (ERP) implementation to Vital Farms’ operations and that it was “fundamental to the operational improvements we are planning”; (2) stated the implementation of the ERP would require the time and attention of “management and key crew members”; (3) indeed, defendant Wrede stated that Vital Farms pushed back the expected implementation date of the ERP to “ensure flawless switchover”; (4) given the stated importance of and management’s knowledge of the issues surrounding the implementation of the ERP, defendants knew, or were reckless in not knowing, that implementing the ERP would result in delays of shipments and/or production; (5) defendants did not warn investors that implementing the ERP would result in delays in shipments and/or production, instead merely couching it as a hypothetical in their risk disclosures; and (6) as a result of the delay in shipments and/or production, Vital Farms would lose important retail shelf space, which would negatively impact Vital Farms’ business and operations.

Class Period

5/8/25 - 2/26/26

Deadline

May 26 2026

Learn More

44

Days Left

PINS

Pinterest, Inc.

Deadline

May 29 2026

Class Period

2/7/25 - 2/12/26

Allegations

(i) Pinterest was experiencing and/or was likely to experience reduced revenues from its advertising partners; (ii) Pinterest overstated its ability to manage the impact of U.S. tariffs on the macroeconomic environment in which the Company operated, including the foreseeable impact on its advertising partners; (iii) the impact of the foregoing on Pinterest’s advertising revenues was significant enough that Pinterest was facing and/or likely to face an imminent restructuring; and (iv) as a result, defendants’ public statements were materially false and misleading at all times.

Class Period

2/7/25 - 2/12/26

Deadline

May 29 2026

Learn More

44

Days Left

ALDX

Aldeyra Therapeutics, Inc.

Deadline

May 29 2026

Class Period

11/3/23 - 3/16/26

Allegations

(1) The results of the reproxalap clinical trials were inconsistent; (2) the inconsistency of the results rendered any positive findings from these trials unreliable and not meaningful; and (3) as a result, defendants’ statements about Aldeyra’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

11/3/23 - 3/16/26

Deadline

May 29 2026

Learn More

47

Days Left

GOSS

Gossamer Bio, Inc.

Deadline

June 1 2026

Class Period

6/16/25 - 2/20/26

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the study design for the Company’s Phase 3 PROSERA study, particularly, controlling for the placebo response at the Latin American testing sites. On February 23, 2026, Gossamer published a press release and hosted a Special Call announcing topline results for its Phase 3 PROSERA study, which failed to meet the primary endpoint of improved six-minute walk distance (6MWD) at Week 24, with a +13.3 meter placebo-adjusted gain (p-0.0320) failing to meet the required 0.025 alpha threshold. Gossamer attributed this miss to patients at Latin American sites performing particularly well on placebo due to enrollment of a heavily-treated lower-risk population. Following this news, the price of Gossamer’s common stock declined from a closing market price of $2.13 per share on February 20, 2026 to $0.42 per share on February 23, 2025, a decline of over 80% in the span of just a single day.

Class Period

6/16/25 - 2/20/26

Deadline

June 1 2026

Learn More

47

Days Left

NUAI

New Era Energy & Digital, Inc.

Deadline

June 1 2026

Class Period

11/4/24 - 12/29/25

Allegations

(1) the Company overstated its progress in its permitting and regulatory filings for its flagship Texas critical data centers project; (2) the Company was involved in a fraudulent scheme “to pocket revenues from hundreds of oil and gas wells in New Mexico” by transferring wells among related entities and then placing liability-bearing companies into bankruptcy to avoid plugging and remediation costs; (3) as a result, the Company’s financial results were false and/or misleading; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/4/24 - 12/29/25

Deadline

June 1 2026

Learn More

54

Days Left

MEDP

Medpace Holdings, Inc.

Deadline

June 8 2026

Class Period

4/22/25 - 2/9/26

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the true state of Medpace's backlog cancellation rate. Defendants continuously touted "well behaved" cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio. On February 9, 2026, Medpace issued a press release announcing the Company's fourth quarter 2025 book-to-bill ratio of 1.04, well below the guidance of 1. 15. Following this news, the price of Medpace's common stock declined dramatically. From a closing market price of $530.35 per share on February 9, 2026, Medpace's common stock price fell to $446. 05 per share on February 10, 2026, a decline of more than 15.9%.

Class Period

4/22/25 - 2/9/26

Deadline

June 8 2026

Learn More

54

Days Left

STLA

Stellantis N.V.

Deadline

June 8 2026

Class Period

2/26/25 - 2/5/26

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the true state of Stellantis’ earnings growth potential, notably, that it was not truly equipped or positioned to grow its adjusted operating income (“AOI”) as forecasted; that electrification was either not truly growing as defendants claimed or that Stellantis was not well positioned to capitalize upon it and convert the opportunity to growth. Instead, Stellantis would ultimately be required to take on considerable charges to adjust its priority, focus, and overall execution in a shift away from battery-powered electric vehicles (“BEV”). On February 6, 2026, Stellantis announced €22 billion in charges alongside a “reset” of the Company’s business and a shortfall, even discounting the charges, against defendants’ previously guided AOI benchmarks. Pertinently, defendants disclosed the charges and reset were due in significant part to the need to shift organizational priorities, stakeholder relationships, supply chains, execution, and quality control due to “an initial overestimation of pace of adoption of electrification in the regions.” Defendants further pointed specifically to “substantially reduced volume and profitability expectations for BEV products.” Following this news, the price of Stellantis’ common stock declined dramatically. From a closing market price of $9.54 per share on February 5, 2026, Stellantis’ stock price fell to $7.28 per share on February 6, 2026, a decline of about 23.69% in the span of just a single day.

Class Period

2/26/25 - 2/5/26

Deadline

June 8 2026

Learn More

54

Days Left

UPST

Upstart, Inc.

Deadline

June 8 2026

Class Period

5/14/25 - 11/4/25

Allegations

(i) the Company's latest iteration of its AI model, Model 22, frequently overreacted to negative macroeconomic signals in performing its risk-separation processes; (ii) accordingly, Model 22’s overall accuracy and propensity to increase loan approval rates was overstated; (iii) Model 22’s overly conservative assessment of credit and macroeconomic conditions was having a significant negative impact on Upstart’s revenue results, rendering the Company’s previously issued FY 2025 revenue guidance unreliable and/or unrealistic; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times

Class Period

5/14/25 - 11/4/25

Deadline

June 8 2026

Learn More

55

Days Left

UHG

United Homes Group, Inc.

Deadline

June 9 2026

Class Period

5/19/25 - 2/22/26

Allegations

(1) the Company’s controlling shareholder, Nieri, intended to force a sale of the Company; (2) Nieri was taking actions to devalue the Company and its financial condition; (3) Nieri leveraged his controlling interest to effectuate that sale, including by effectively forcing the dissident directors to resign; and (4) as a result of the foregoing, Nieri was not acting in the best interests of the Company and public investors.

Class Period

5/19/25 - 2/22/26

Deadline

June 9 2026

Learn More

View All Deadlines

News

Stay informed with the latest in settlement notices, case updates, publications, analyst reports, and more.
View All News

Learn More

Broken Trust at Franklin BSP? Investors Question the Realty Behind the Dividend
Franklin BSP Realty Trust told investors the dividend was solid. $0.355 cents a quarter. Presented as sustainable. Supported by confidence in future coverage. But behind the scenes, the math was not adding up. On November 5, 2024, executives admitted earnings were not covering the dividend. Still, they said they were “confident” in its long term...Read more

April 14, 2026

Learn More

Iceberg Ahead: Lawsuit Claims Snowflake Downplayed Major Revenue Threats
Snowflake Inc. told investors the growth story was still intact. Consumption was stabilizing. $10 billion in product revenue by 2029 was still the goal. But behind the scenes, cracks were forming. On June 27, 2023, executives assured investors usage was “back where we’d expect it to be.” Through August and November, they repeated that consumption...Read more

April 13, 2026

Learn More

From Takeoff to Tailspin: Navan Shareholders Allege Damaging Offering Omissions
Navan, Inc. promised investors rapid growth. 33% percent revenue growth. 32% booking growth. A platform built for customers of all sizes across industries. Then came the IPO in October 2025. Shares priced at $25. Nearly $920 million raised. Confidence was high. But behind the scenes, something wasn’t in the spotlight. On October 31, the same...Read more

April 10, 2026

View All News

Our World-Class Team

Levi & Korsinsky’s attorneys are admitted in over 40 state, federal, and appeal courts across the country. We have the specialized securities skills to achieve outstanding results, and our impressive variety of backgrounds means that we can go up against large companies of any kind and win. Our powerhouse attorneys have backgrounds in accounting, engineering, SEC enforcement, mathematics, regulatory analysis, international business, and prosecution, to name just a few. . .

View Attorneys